HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
about
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned.Natural killer cell education in human health and disease.
P2860
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@ast
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@en
type
label
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@ast
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@en
prefLabel
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@ast
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@en
P2093
P2860
P356
P1476
HLA-Bw4-I-80 Isoform Different ...... mab-Based Cancer Immunotherapy
@en
P2093
Amy K Erbe
Andrew L Gilman
Arlene Naranjo
Eneida A Mendonca
Fangxin Hong
Jacquelyn A Hank
Jeffrey S Miller
John M Maris
Julie R Park
P2860
P356
10.3389/FIMMU.2017.00675
P50
P577
2017-06-12T00:00:00Z